Abstract

Amcor plc will report its fiscal fourth-quarter results on August 12, 2026 Pre-MKt; this preview outlines consensus revenue, margin, and adjusted EPS expectations alongside recent performance trends and institutional sentiment.

Market Forecast

- For the current quarter, the market projects revenue of 6.05 billion US dollars, EBIT of 762.37 million US dollars, and adjusted EPS of 1.19, implying year-over-year growth rates of 26.48%, 32.08%, and 9.94% respectively. Forecast commentary implies year-over-year momentum across the P&L, with EBIT projected to grow faster than revenue. - The company’s prior report points to a gross profit margin outlook near the low 20% range and a net profit margin in the mid-single digits; if achieved, a similar gross margin would be roughly consistent with recent prints while net margin expansion would depend on mix and costs. Adjusted EPS growth is expected to outpace revenue given operating leverage from cost actions. - Main business highlights and outlook: flexible packaging remains the revenue anchor, with rigid packaging contributing the balance; guidance commentary from recent quarters suggests stable demand in consumer staples offset by uneven performance in healthcare and specialty categories. - Most promising segment: flexible packaging, modeled at 3.25 billion US dollars this quarter, with improving year-over-year trends supported by volume normalization and pricing carryover.

Last Quarter Review

- Amcor plc posted revenue of 5.91 billion US dollars, a gross profit margin of 20.12%, GAAP net profit attributable to shareholders of 278.00 million US dollars, a net profit margin of 4.70%, and adjusted EPS of 0.96, with year-over-year adjusted EPS growth of 6.67%. - A key highlight was stronger operating execution, with EBIT of 687.00 million US dollars exceeding internal and external estimates. Main business highlights: flexible packaging revenue was 3.25 billion US dollars and rigid packaging revenue was 2.66 billion US dollars; flexible led the top line amid steadier demand and mix benefits.

Current Quarter Outlook (with major analytical insights)

Main business: Flexible packaging (core driver)

Flexible packaging represents the largest revenue base at approximately 3.25 billion US dollars in the prior quarter and is expected to maintain leadership given its exposure to daily-use consumer packaged goods. With revenue forecast growth in the mid-20% range for the consolidated group, flexible packaging performance will be closely tied to volume normalization after destocking across food and beverage customers and to carryover from price adjustments made during the raw-material cost inflation cycle. If resin and aluminum input prices remain relatively stable, gross margin in flexible packaging should hold near recent prints, helping preserve the consolidated gross profit margin around the low 20% range. The segment’s operating leverage, together with ongoing footprint optimization, could allow EBIT to scale faster than sales, consistent with the forecasted EBIT growth above revenue.

Most promising business: Flexible packaging (healthcare and premium sub-categories)

Within flexible, healthcare and premium specialty formats appear positioned for better mix contribution as elective procedure volumes normalize and branded consumer products lean into higher value packaging. This sub-mix supports incremental margin expansion versus mainstream SKUs. Given the company’s disciplined capital allocation toward high-return lines and automation, the earnings sensitivity is skewed to a modest upside if specialty volumes meet plan. A 26% revenue growth forecast and a 32% EBIT growth forecast indicate positive mix and productivity effects; if realized, adjusted EPS of 1.19 would reflect high single-digit growth even after FX and interest headwinds.

Key stock price swing factors this quarter

Investors will focus on volume recovery across staples and healthcare, where order patterns have been uneven; confirmation of double-digit percent EBIT growth relative to revenue would support the margin recovery narrative. Input costs are a second swing factor: stable resins would help sustain the 20% gross margin zone, while any sharp commodity moves could compress margins and earnings. Lastly, free cash flow conversion and working-capital discipline are likely to shape sentiment, as improved receivables and inventory turns could validate the operating improvements embedded in EPS forecasts.

Analyst Opinions

Across recent institutional previews, the balance of commentary skews neutral-to-cautious, with a majority emphasizing disciplined cost control and stable consumer-staples demand tempered by uneven healthcare and specialty trends. Analysts note that consensus implies revenue of 6.05 billion US dollars and adjusted EPS of 1.19, with EBIT growth outpacing sales; several warn that upside depends on volume elasticity and commodity stability. Well-followed research houses characterize the risk-reward as balanced into the print, pointing to improving internal execution but limited visibility on a sustained acceleration beyond near-term normalization. Given this balance, the prevailing stance is to watch for confirmation of volume recovery and incremental margin expansion rather than anticipate a pronounced beat.